A repeat dose of the drug 186RNL for glioma that came back
Original title: Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests another dose of 186RNL in people with glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary who already had this drug once.
Who this trial is for. This trial is for people whose glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary came back and who already had a treatment with 186RNL. It tests a single dose of 186RNL given into the fluid spaces of the brain through a thin tube called a catheter. The study is running at more than one site, and everyone involved knows who gets the drug.
Where it stands. The trial has not reported results. The team is watching how safe the dose is and how well people handle it. They are also looking at how well it works. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: For now this tells us nothing about whether a repeat dose helps. If you have had 186RNL before and your tumor came back, you could ask your care team about this study. They can tell you if it makes sense for you.
What it doesn't mean: This does not mean a repeat dose works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.